Hypercalcemia Management — free guideline decision tool
This tool guides hypercalcemia management by calcium level, symptoms, and renal function, framing fluids, antiresorptives (bisphosphonate/denosumab), calcitonin, and special-etiology therapy.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Calcium level | Moderate (3.0–3.5 / 12–14) |
|---|---|
| Symptoms | Symptomatic |
| Renal impairment or bisphosphonate contraindication | No |
→DispositionModerate/symptomatic: aggressive calcium-lowering
- First-line fluids：IV normal saline to correct dehydration and promote urinary calcium excretion (target urine output); after adequate fluids, add loop diuretic (furosemide) for those at risk of volume overload (heart failure/renal impairment) — never give a loop diuretic before fluids
- Inhibit bone resorption：IV bisphosphonate: zoledronic acid infused over (superior to pamidronate; onset 2–4 days); switch to denosumab in renal impairment
- Rapid short-term：Calcitonin SC/IM is rapid but short-acting
| Calcium level | Severe (> 3.5 mmol/L / > 14 mg/dL) |
|---|---|
| Symptoms | Asymptomatic |
| Renal impairment or bisphosphonate contraindication | Yes |
→DispositionSpecific treatment and doses follow current guidelines and local protocols; this page does not list them. [Pending update] Unsourced specific doses/regimens on this page are temporarily hidden pending item-by-item review against the cited guideline texts.
- First-line fluids：IV normal saline to correct dehydration and promote urinary calcium excretion (target urine output); after adequate fluids, add loop diuretic (furosemide) for those at risk of volume overload (heart failure/renal impairment) — never give a loop diuretic before fluids
- Inhibit bone resorption：Denosumab (not renally cleared, suitable for renal impairment or bisphosphonate contraindication; also for refractory/recurrent)
- Rapid short-term：Calcitonin SC/IM is rapid but short-acting
Common questions
What is Hypercalcemia Management?
This tool guides hypercalcemia management by calcium level, symptoms, and renal function, framing fluids, antiresorptives (bisphosphonate/denosumab), calcitonin, and special-etiology therapy.
How is Hypercalcemia Management calculated? What is the core formula?
Mild asymptomatic Moderate-severe/symptomatic.
When is Hypercalcemia Management used?
Specific treatment and doses follow current guidelines and local protocols; this page does not list them. [Pending update] Unsourced specific doses/regimens on this page are temporarily hidden pending item-by-item review against the cited guideline texts.
What are the key clinical points for Hypercalcemia Management?
reserve it for volume overload after rehydration. (original synthesis · not guideline verbatim) Denosumab is preferred when renal impairment or a bisphosphonate contraindication is present, and for refractory/recurrent cases. Calcitriol-mediated hypercalcemia (vitamin D toxicity, granulomatous disease, lymphoma) responds to glucocorticoids.
What are the limits and cautions when using Hypercalcemia Management?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
Does Hypercalcemia Management upload patient data? Where is it calculated?
Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.
How is Hypercalcemia Management calculated in practice? Can you show a worked example?
Inputs: Calcium level Moderate (3.0–3.5 / 12–14), Symptoms Symptomatic, Renal impairment or bisphosphonate contraindication No → Result: Disposition Moderate/symptomatic: aggressive calcium-lowering（First-line fluids: IV normal saline to correct dehydration and promote urinary calcium excretion (target urine output); after adequate fluids, add loop diuretic (furosemide) for those at risk of volume overload (heart failure/renal impairment) — never give a loop diuretic before fluids, Inhibit bone resorption: IV bisphosphonate: zoledronic acid infused over (superior to pamidronate; onset 2–4 days); switch to denosumab in renal impairment, Rapid short-term: Calcitonin SC/IM is rapid but short-acting） Inputs: Calcium level Severe (> 3.5 mmol/L / > 14 mg/dL), Symptoms Asymptomatic, Renal impairment or bisphosphonate contraindication Yes → Result: Disposition Specific treatment and doses follow current guidelines and local protocols; this page does not list them. [Pending update] Unsourced specific doses/regimens on this page are temporarily hidden pending item-by-item review against the cited guideline texts.（First-line fluids: IV normal saline to correct dehydration and promote urinary calcium excretion (target urine output); after adequate fluids, add loop diuretic (furosemide) for those at risk of volume overload (heart failure/renal impairment) — never give a loop diuretic before fluids, Inhibit bone resorption: Denosumab (not renally cleared, suitable for renal impairment or bisphosphonate contraindication; also for refractory/recurrent), Rapid short-term: Calcitonin SC/IM is rapid but short-acting）
Run Hypercalcemia Management now
This tool guides hypercalcemia management by calcium level, symptoms, and renal function, framing fluids, antiresorptives (bisphosphonate/denosumab), calcitonin, and special-etiology therapy.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.